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40 words summary: This study reveals renal transplantation-specific risk factors 
for invasive aspergillosis: leukopenia and duration of renal replacement therapy for 
early infection, CMV seropositivity of the donor for late infection. Leukopenia, 
disseminated infection and serum galactomannan index correlate with mortality. 
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ABSTRACT 
 
Background: Transplant recipients are at risk for invasive aspergillosis (IA), 
associated with a significant mortality rate. Renal transplantation-specific risk 
factors have not been established.   
 
Methods: Forty-one adult kidney transplant recipients diagnosed with proven or 
probable IA from 1995 through 2013 were identified by search of the computerized 
patient files in the University Hospitals Leuven.  The control population in this 1:2 
case control study consisted of the two patients who received a kidney transplant 
immediately before and after each identified patient and did not develop IA (n = 82).  
Results: Leukopenia after kidney transplantation increased the risk of IA among all 
patients (OR, 2.345; 95% CI, 1.084-5.071). For early-onset infection (i.e., occurred 
during the first 3 months after transplantation), a longer duration of renal 
replacement therapy pre-transplant and the occurrence of leukopenia were risk 
factors (OR per year, 1.192; 95% CI, 1.006-1.413 and OR, 3.346; 95% CI, 1.063-
10.527, respectively), while donor CMV seropositivity increased the risk for late-
onset IA (i.e., occurred >3 months after transplantation) (OR, 3.677; 95% CI, 1.388-
9.743).  Twelve-week mortality rate was 39%. Disseminated infection, leukopenia 
and the height of the serum galactomannan index were associated with an increased 
risk of death (HR, 5.080; 95% CI, 1.740-14.830 and HR, 3.198; 95% CI, 1.183-8.649 
and HR, 1.371; 95% CI, 1.123-1.674, respectively).  
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Conclusions: Prolonged renal replacement therapy before kidney transplantation 
increases the risk of IA early after transplantation. The height of the serum 
galactomannan index predicts mortality.  
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INTRODUCTION 
 
Although Aspergillus spores are ubiquitous in nature, invasive infection is 
uncommon, and occurs most frequently in the setting of immunosuppression 
associated with therapy for hematologic malignancies, hematopoietic cell 
transplantation, or solid organ transplantation [1].  The relative incidence in liver, 
lung and heart transplantation seems to outnumber the incidence in renal 
transplantation [1, 2]. This has been partly explained by the healthier preoperative 
state of renal transplant recipients [2]. 
 
The largest cohort of renal transplant recipients who developed invasive 
aspergillosis (IA) has been decribed by Baddley et al. and included 47 cases [3]. This 
study was a case series as no risk factors were described. To the best of our 
knowledge, the largest study investigating specific risk factors in solid organ 
transplantation included only 10 renal transplant recipients [4].  
 
As IA is associated with a significant crude mortality rate [3, 5], a better 
understanding of the risk factors and prognostic factors are of importance, to guide 
preventive measures, diagnostic work-up, and therapeutic decisions.  
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PATIENTS AND METHODS 
 
Study patients 
This retrospective study included all patients who underwent renal transplantation 
at the University Hospitals Leuven, Belgium. Adult kidney transplant recipients 
diagnosed with IA from 1995 through 2013 were identified in the computerized 
patient files. Patient data were collected from a prospectively maintained database 
and by additional chart review. Day of diagnosis was defined as the first day of 
antifungal therapy. Cases of IA were classified according to Hope et al. [6] and as 
“probable” or “proven” according to the revised standard criteria from the European 
Organization for Research and Treatment of Cancer-Mycoses Study Group [7]. The 
control population in this 1:2 case control study consisted of the two patients who 
underwent kidney transplantation immediately before and after each identified 
patient and did not develop IA.  
Kidney transplant protocols: immunosuppression and prophylactic measures 
The immunosuppressive regimen varied according the time period, with 
cyclosporine and azathioprine being largely replaced by tacrolimus and 
mycophenolate mofetil from 1999 onwards. Only 6 patients (3 cases and 3 controls) 
received an mTor inhibitor (sirolimus), while all patients received corticosteroids. 
Induction therapy (anti-thymocyte globulin or anti-interleukin-2 receptor 
antibodies) was given to highly immunized recipients (panel reactive antibody 
above 30%, North African origin, second or subsequent transplantation) and living 
donation [8] since 1995.  Rejection episodes were treated with methylprednisolone 
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in a tapering regimen. In patients undergoing transplantation after 1998, 
prophylaxis against CMV infection with ganciclovir was given when recipient and/or 
donor were CMV seropositive. Pneumocystis jirovecii infection prophylaxis with 
trimethoprim-sulfamethoxazole was given to all patients in the first 3 months 
following transplantation. No systemic antifungal prophylaxis was used.  
 
Diagnostic testing  
Physical examination, chest radiography and/or chest CT scan and blood cultures 
were performed in all febrile patients at clinical suspicion of infection. Additional 
samples for culture were obtained as clinically indicated. Tissue and 
bronchoalveolar lavage (BAL) fluid samples were evaluated for the presence of 
fungi by use of standard histopathologic and microbiological techniques. Since 1999 
the Platelia Aspergillus galactomannan EIA was performed on serum samples when 
a diagnosis of IA was suspected. Since 2003, it was performed on BAL samples as 
well.  A galactomannan index of ≥0.5 was used to define positivity, both in serum 
and BAL [9, 10].  
 
Treatment regimens for invasive aspergillosis  
Before 2003, amphotericin B products were administered as standard therapy. 
Since 2003, voriconazole became the drug of choice. Caspofungin was used in 4 
patients and posaconazole in 1 patient, due to voriconazole intolerance/toxicity or 
due to co-infection with resistant fungi.  
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Data analysis 
The primary objective of the study was to determine the risk factors in kidney 
transplant recipients by performing a case-control study.  We included the following 
recipient variables: age, gender, duration of renal replacement therapy (for second 
and subsequent transplantations the duration after failure of the previous 
transplant was used), smoking habits, pre-existing chronic lung disease, diabetes 
mellitus prior to transplantation, respiratory function measured as part of the pre-
transplant work-up, total number of HLA mismatch, use of basiliximab or anti-
thymocyte globulin, donor and/or recipient CMV seropositivity and its prophylaxis, 
and the occurrence of leukopenia (< 3000/μL) and acute rejection after 
transplantation. Results from the obtained cultures and biopsies were described, in 
addition to the galactomannan optical density index on serum and BAL samples. The 
use of specific immunosuppressive drugs could not be included as variable for risk 
factor analysis, because of time-related changes in the patients’ immunosuppressive 
regimen.  Recipients that developed IA before month 3 after transplantation were 
analyzed separately as ‘early IA', and the recipients with IA after month 3 as ‘late IA’ 
in concordance with previous studies [4, 11]. 
Continuous data were expressed as the mean ± SD and 95% CI for normally 
distributed data and as median and interquartile range for skewed data. Discrete 
variables were expressed as percentages. Continuous variables were compared 
using Student’s unpaired t test or the Mann-Whitney U test, where appropriate. 
Proportions were compared using the χ2 test or the Fisher’s exact test. Odds ratios 
(OR) were calculated by univariate binary logistic regression analysis. 
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The secondary objective of this study was to determine the prognostic factors of IA 
after kidney transplantation. Mortality at week 12 after diagnosis was used as an 
end-point in concordance with other studies [3, 12]. For the mortality analyses, the 
same host variables were included, but instead of leukopenia after transplantation, 
leukopenia (< 3000/μL) at the time of presentation with the infection was included.  
Survival at week 12 after diagnosis was estimated with Kaplan-Meier curves and 
compared between groups using log-rank P values. Hazard ratios (HR) were 
calculated by univariate Cox proportional hazards analysis.  All statistical tests were 
2-tailed, and the threshold of statistical significance was P <.05. 
  
 
 
RESULTS 
 
Clinical presentation 
Forty-one cases of IA after kidney transplantation were identified between 1995 
and 2013: 24 males and 17 females, with a mean age of 61 years ± 12 at diagnosis. 
Eleven patients had leukopenia at presentation (27%), and 7 patients (17%) had a 
CMV infection prior or during the infection with Aspergillus. Other patient 
characteristics are summarized in Table 1.  
The distribution of IA episodes according to the time of diagnosis after 
transplantation is presented in Figure 1. The median time to the development of IA 
was 141 days (72-522). Fifteen recipients (37%) developed early IA, and 26 
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recipients (63%) developed late IA. The infection was proven IA in 18 recipients 
(44%) and probable IA in 23 recipients (56%). Five cases developed disseminated 
infection (i.e., with involvement of ≥2 non-contiguous organs). Four of these 
presented with symptoms of invasive pulmonary aspergillosis, one presented with 
an intraocular infection. All patients with disseminated IA died. In four, myocardial 
aspergillosis could be identified postmortem. In all cases with positive cultures (38 
from 41 patients), A. fumigatus was identified as the pathogen. In one case, there 
was a co-infection with A. niger. From the 36 patients with localized IA, 30 had 
invasive pulmonary aspergillosis, four had invasive bronchial aspergillosis, one 
cerebral abscess and one acute invasive sinusitis extending to the mastoid bone and 
cerebrum. In the 34 patients with IA of the lower respiratory tract, positive cultures 
could be obtained in 10 out of 22 sputum samples, 14 out of 22 bronchus aspirate 
samples, 17 out of 27 BAL samples, 0 out of 6 pleural fluid samples and 3 out of 4 
bronchus biopsy samples. Microscopy of bronchus aspirate or BAL fluid could 
demonstrate fungal hyphae in 2 out of 12 samples. The galactomannan index was 
positive in 14 out of 15 BAL fluid samples (mean index of 3.9 ± 2.5). In the total 
patient cohort, the galactomannan index was positive in 11 out of 33 serum samples 
(mean index of 1.6 ± 2.9).  
 
 
Risk factors 
The occurrence of leukopenia after transplantation increased the risk of IA (OR, 
2.345; 95% CI, 1.084-5.071; P=0.029), whereas smoking status, gender, age, 
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diabetes mellitus prior to transplantation, chronic lung disease, duration of renal 
replacement therapy prior to transplantation, total number of HLA mismatch, 
presence of HLA antibodies, use of induction therapy or CMV prophylaxis, poor 
respiratory function tests prior to transplantation, the occurrence of CMV infection 
and acute rejection did not (Table 1).  
 
Recipients with early IA had a significantly longer duration of renal replacement 
therapy before transplantation compared to the controls (3.57 (2.02–5.15) vs. 2.04 
(1.22-3.05) years; P=0.019). Leukopenia in the first 3 months after transplantation 
was also associated with early IA (47% vs. 21%; P=0.049).  In contrast, the duration 
of renal replacement therapy before transplantation did not differ between patients 
with late IA and the controls (1.48 (1.09-3.51) vs. 2.04 (1.22-3.05) years, P=0.808). 
The occurrence of leukopenia was not a significant risk factor for late IA (54% vs. 
21%, P=0.119). CMV positivity of the donor increased the risk of late IA (61% vs. 
29%, P=0.007). There was a trend for increased risk with seropositivity of the 
recipient (71% vs; 47%, P=0.051), while CMV prophylaxis (50% vs. 39%, P=0.323) 
and CMV infection (23% vs. 15%, P=0.367) did not increase the risk. There was also 
a trend for increased risk of late IA for recipients with a chronic respiratory 
disease(19% vs. 6%, P=0.058)(Table 2).  
 
Survival 
The mortality rate at week 12 for patients with IA was 39% (73% before 2003 and 
19% since 2003). The height of the serum galactomannan index predicted 12-week 
 12 
mortality (HR, 1.371; 95% CI, 1.123 – 1.674) (Table 3). Using ROC curve and Youden 
statistic, the optimal cutoff for the serum galactomannan level to predict the risk for 
death was an index of 2.0. In addition, leukopenia at the time of presentation, 
disseminated infection and infections acquired after 2002 were associated with 12-
week mortality rate (HR, 3.198; 95% CI, 1.183 – 8.649; HR, 5.080; 95% CI, 1.740 – 
14.830; and HR, 0.156; 95% CI 0.053 – 0.454). There was a trend to increased 
mortality according to smoking status (Table 3).  
 
 
DISCUSSION 
 
Over the past decade, risk factors for solid organ transplant-associated IA and its 
prognostic factors have been identified [3, 4], and this has improved early diagnosis 
and treatment [13-16]. The relatively lower incidence among kidney transplant 
recipients compared to other organ transplant recipients explains the lack of studies 
focusing on IA in this population. By comparing 41 cases with 82-non-infected 
recipients, transplanted immediately before and after each case, we could identify 
risk factors specific for kidney transplant recipients.  
The risk of IA early after transplantation increased with prolonged renal 
replacement therapy before transplantation. In solid organ transplantation in 
general, renal failure and the need of renal replacement therapy after 
transplantation are independent risk factors for IA [4]. In liver transplantation 
recipients it is one of the most significant risk factors for IA, leading to a 15-to 25-
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fold-greater risk [19, 20]. Our results demonstrate for the first time an increased 
susceptibility with longer duration of renal replacement therapy before 
transplantation.  
Similar to previous studies in solid-organ transplantation, leukopenia increased the 
risk for IA [4]. We choose a less strict definition of leukopenia compared to studies 
in haematology to determine risk factors specific for the transplant setting. This is in 
agreement to a similar case-control study on IA in solid-organ transplantation [4]. 
The retrospective design of this study precluded us to obtain information about 
duration of leukopenia. 
 
There was a trend to an increased risk for late IA in recipients with a chronic 
respiratory disease. Others have previously suggested an association between 
respiratory dysfunction and risk of IA, as patients with chronic obstructive 
pulmonary disorder (COPD) are at risk of invasive pulmonary aspergillosis and their 
increased susceptibility does not seem to be explained by exposure to steroids alone 
[5, 21-23].  
 
In line with previous reports [24], we did not find an association between acute 
rejection and the occurrence of IA. We did find an association between donor CMV 
positivity and the risk for late IA, similar to what has been observed in liver 
transplant recipients [25]. CMV infection is known to induce an immunosuppressed 
state [26] and its therapy can induce leukopenia.  In liver transplant recipients CMV 
disease is associated with invasive fungal disease [25]. In our cohort, 17% of cases 
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had a CMV infection immediately prior or during the infection with Aspergillus. 
However, the occurrence of CMV infections after transplantation was not 
significantly higher compared to the control group.  
 
The overall 12-week mortality of 39% is lower than the mortality previously 
described among HSCT and transplant patients [27][5], but comparable to a more 
recent study in solid organ transplantation [3]. Mortality decreased after 2002, 
when voriconazole was introduced in our therapy regimens. The prognostic effect of 
this time point was more pronounced than the effect of treatment regimens 
including voriconazole. However, this study was not designed to investigate the 
prognostic role of a specific antifungal therapy. In addition, many patients received 
subsequently different regimens, for example due to renal function deterioration.  
Patients with leukopenia at presentation had an increased risk of death. A higher 
case fatality rate in patients with neutropenia has already been observed [5], but 
has not been reported for solid organ transplant recipients in specific [4]. In 
addition, the height of the serum galactomannan test correlated with mortality, 
whereas the BAL galactomannan did not. This is in agreement with what has been 
reported in HSCT patients [28] and patients with hematologic cancer [29]. We are 
the first to describe this association in solid organ transplant recipients. In contrast, 
the serum galactomannan test lacks sensitivity for IA diagnosis in solid organ 
transplant recipients, whereas the sensitivity of the galactomannan test in BAL fluid 
is high in this population [16, 30, 31]. The higher serum galactomannan level is 
thought to represent a higher Aspergillus burden and/or increased micro- or macro-
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dissemination [28]. In our cohort, disseminated IA increased the risk of death, 
similar to what has been reported elsewhere [3, 12, 27].  
We could not observe an association between the respiratory function measured 
pre-transplant and mortality after IA. In a study of HSCT patients, a compromised 
respiratory function pre-transplant was the only host factor independently 
associated with an increased risk for death, but the criteria used to define severe 
pulmonary function abnormality were not reported in this study [27].  
 
The strength of our study is the relatively large case cohort among kidney 
transplant recipients compared to other studies, the focus on kidney transplantation 
alone and the inclusion of only proven and probable cases. However, the number of 
cases was too low to perform accurate multivariate testing. In addition, the 
retrospective design in this large time frame precluded the collection of all variables 
in all patients.  
 
In conclusion, the duration of renal replacement therapy and the occurrence of 
leukopenia increased the risk for early IA after kidney transplantation. Mortality 
rate was highest among recipients with leukopenia, disseminated infection and 
higher levels of serum galactomannan test. 
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Table 1: Patient characteristics. Continuous variables were compared using 
Student’s unpaired t test or the Mann-Whitney U test, where appropriate. 
Proportions were compared using the χ2 test or the Fisher’s exact test, where 
appropriate. 
 
Variable cases (n=41)  controls (n=82) P-value 
Gender (male/female) 22/19 50/32 0.734 
Age1 (years) 58 ± 12 55 ± 12 0.155 
Smoking1 (yes/no) 5/33 (15%) 5/79 (6%) 0.156 
Diabetes mellitus1 (yes/no) 10/41 (24%) 15/82 (18%) 0.428 
Chronic respiratory disorder1 (yes/no) 7/41 (17%) 5/82 (6%) 0.102 
Duration RRT1 (years) 2.85 (IQR 2.53) 2.04 (IQR 1.83) 0.268 
Total number of HLA mismatch 3 ± 1 3 ± 2 0.375 
HLA antibodies 3/39 (8%) 6/80 (8%) 1.000 
CMV positive recipient 23/36 (64%) 34/72 (47%) 0.102 
CMV positive donors 16/38 (42%) 22/74 (30%) 0.190 
CMV D+/R- 5/35 (14%) 12/70 (17%) 0.708 
CMV prophylaxis 22 (54%) 32 (39%) 0.123 
Induction therapy 13/41 (32%) 20/82 (24%) 0.388 
FEV1 (%) 86 ± 20 91 ± 20 0.234 
FEFV1/FVC 77 ± 7 80 ± 10 0.216 
TLC (%) 93 ± 15 98 ± 21 0.283 
DLCO (%) 69 ± 20 72 ± 20 0.520 
CMV infection2 8/41 (22%) 12/82 (15%) 0.309 
Acute rejection2 14/40 (35%) 23/82 (28%) 0.290 
Leukopenia2 22/41 (54%) 30/82 (37%) 0.029 
 
 
NOTE 1At transplantation time point, 2At any time point post-transplant 
RRT, renal replacement therapy; FEV1, forced expiratory volume in 1 second; FVC, 
forced vital capacity; TLC, total lung capacity; DLCO, diffusion capacity 
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Table 2: Risk factors for early and late invasive aspergillosis by univariate 
logistic regression analysis.  
  Early IA   Late IA 
Variable 
P-
value OR (95% CI)   
P-
value OR (95% CI) 
Gender  0.305 1.786 (0.590 - 5.403) 
 
0.766 1.146 (0.468 - 2.806) 
Age1 0.281 1.028 (0.977 - 1.082) 
 
0.255 1.024 (0.983 - 1.066) 
Smoking1 0.190 3.289 (0.555 - 19.499) 
 
0.273 2.337 (0.512 - 10.658) 
Diabetes mellitus1 0.456 1.624 (0.454 - 5.807) 
 
0.592 1.340 (0.459 - 3.908) 
Chronic respiratory disorder1 0.332 2.369 (0.415 - 13.525) 
 
0.056 3.667 (0.970 - 13.866) 
Duration RRT (years) 0.042 1.192 (1.006 - 1.413) 
 
0.564 0.935 (0.744 - 1.175) 
Total HLA mismatch 0.271 1.239 (0.846 - 1.815) 
 
0.712 1.059 (0.781 - 1.437) 
HLA antibodies 0.910 0.881 (0.098 - 7.893) 
 
0.893 1.121 (0.211 - 5.954) 
CMV positive recipient 0.667 1.277 (0.419 - 3.895) 
 
0.056 2.794 (0.974 - 8.015) 
CMV positive donor 0.207 0.364 (0.076 - 1.748) 
 
0.009 3.677 (1.388 - 9.743) 
CMV D + R - 0.326 0.345 (0.041 - 2.882) 
 
0.768 1.208 (0.343 - 4.259) 
Use of CMV prophylaxis 0.305 1.786 (0.590 - 5.403) 
 
0.324 1.562 (0.643 - 3.796) 
Induction therapy 0.216 2.067 (0.655 - 6.523) 
 
0.795 1.142 (0.419 - 3.112) 
FEV1 < 90% 0.068 3.720 (0.909 - 15.220) 
 
0.988 0.992 (0.341 - 2.888) 
FEV1/FVC < 70 0.883 1.136 (0.209 - 6.159) 
 
0.504 1.573 (0.416 - 5.940) 
TLC < 90% 0.928 1.071 (0.242 - 4.743) 
 
0.339 1.750 (0.555 - 5.514) 
DLCO < 60% 0.990 1.010 (0.232 - 4.399) 
 
0.533 1.496 (0.422 - 5.300) 
FEV1/FVC < 70 or TLC < 90% 
or DLCO < 60% 
0.526 1.548 (0.401 - 5.975) 
 
0.227 2.212 (0.610 - 8.019) 
CMV infection2 0.999 / 
 
0.318 1.750 (0.583 - 5.251) 
Acute rejection2 0.084 2.712 (0.874 - 8.420) 
 
0.996 0.998 (0.368 - 2.704) 
Leukopenia2 0.039 3.346 (1.063 - 10.527)   0.122 2.022 (0.828 - 4.936) 
 
NOTE 1At transplantation time point, 2In the first 3 months post-transplant for early 
IA risk factor analysis and at any time point post-transplant for late IA risk factor 
analysis.  
RRT, renal replacement therapy; FEV1, forced expiratory volume in 1 second; FVC, 
forced vital capacity; TLC, total lung capacity; DLCO, diffusion capacity 
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Table 3: Risk factors for week 12 mortality of invasive aspergillosis by 
univariate Cox proportional hazards analysis.  
Variable P-value HR (95% CI) 
Gender  0.460 1.448 (0.543 - 3.863) 
Age at diagnosis of IA 0.111 0.970 (0.934 - 1.007) 
Smoking1 0.069 3.457 (0.909 - 13.143) 
Diabetes mellitus1 0.075 0.159 (0.021 - 1.202) 
Chronic respiratory disorder1 0.201 0.267 (0.035 - 2.023) 
Duration RRT (years) 0.453 1.063 (0.906 - 1.248) 
Total HLA mismatch 0.749 1.061 (0.737 - 1.528) 
HLA antibodies 0.578 1.523 (0.346 - 6.710) 
CMV positive recipient 0.180 0.511 (0.192 - 1.365) 
CMV positive donor 0.154 2.052 (0.763 - 5.516) 
Use of CMV prophylaxis 0.664 1.251 (0.455 - 3.443) 
Induction therapy 0.347 0.581 (0.187 - 1.802) 
FEV1 < 90% 0.320 0.547 (0.167 - 1.796) 
FEV1/FVC < 70 0.228 0.030 (0.000-8.969) 
TLC < 90% 0.987 1.010 (0.285 - 3.584) 
DLCO < 60% 0.938 1.057 (0.264 - 4.233) 
FEV1/FVC < 70 or TLC < 90% or DLCO < 60% 0.789 0.827 (0.207 - 3.313) 
CMV infection prior or during IA 0.884 0.896 (0.203 - 3.947) 
IA following acute rejection 0.257 1.774 (0.658 - 4.778) 
Leukopenia at clinical presentation of IA 0.022 3.198 (1.183 - 8.649) 
Disseminated vs. localized IA 0.003 5.080 (1.740 - 14.830) 
Proven vs. probable IA 0.104 2.319 (0.841 - 6.393) 
Early vs. late IA 0.971 0.981 (0.356 - 2.700) 
GM index in serum 0.002 1.371 (1.123 - 1.674) 
GM index in BAL 0.243 1.742 (0.687 - 4.421) 
IA after 2002 0.001 0.156 (0.053 - 0.454) 
Therapy containing voriconazol 0.079 0.340 (0.102 - 1.133) 
 
NOTE 1At transplantation time point, 2At any time point post-transplant 
RRT, renal replacement therapy; FEV1, forced expiratory volume in 1 second; FVC, 
forced vital capacity; TLC, total lung capacity; DLCO, diffusion capacity; IA, invasive 
aspergillosis; GM, galactomannan; BAL, bronchoalveolar lavage. 
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Figure legends: 
 
Figure 1: Distribution of the time frame between kidney transplantation and 
diagnosis of invasive aspergillosis. 
 
Figure 2: Kaplan Meier curves for 12 week survival according to A. 
galactomannan level (GM) in serum above or below 2, B. leukopenia at presentation, 
C. disseminated nature of the infection. 
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Figure 1. 
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Figure 2. 
 
 
  
